Dr. Johanne
Kaplan highlights need for precision selectivity for
the toxic form of amyloid beta in narrated overview
TORONTO and CAMBRIDGE, MA, Nov. 7,
2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX:
PMN) (OTCQB: ARFXF), a biotechnology company focused on the
discovery and development of antibody therapeutics targeting toxic
oligomers implicated in the development of neurodegenerative
diseases, posted a narrated overview of its next-generation
amyloid-beta (Aβ)-targeting drug candidate, PMN310 for Alzheimer's
disease (AD), juxtaposed with Biogen's first-generation candidate,
aducanumab. The narrative details PMN310's superior binding to the
toxic form of Aβ, amyloid beta oligomers (AßOs), potentially
without the dose-limiting side effect, ARIA-E (brain swelling),
associated with aducanumab. Upon regulatory approval of aducanumab,
PMN310 is positioned to be a next-generation,
amyloid-beta-targeting candidate for AD.
Biogen has announced plans to submit aducanumab to the U.S. Food
and Drug administration (FDA) for approval. As part of its
announcement, the company noted the potential implication of its
decision for similar approaches targeting amyloid beta. As a
next-generation approach to targeting Aβ, PMN310 offers precision
selectivity for AßOs, which hundreds of studies indicate are a
root cause of neuronal death in AD. In pre-clinical studies,
PMN310, unlike aducanumab, shows virtually no binding to amyloid
plaque, suggesting a best-in-class profile with an opportunity for
higher dosing without ARIA-E.
Stated Dr. Johanne Kaplan, Chief
Development Officer for ProMIS Neurosciences: "As the renowned
neuroscience leader Dr. Dennis J.
Selkoe wrote in a recent STAT First Opinion byline, the
first therapy for Alzheimer's will 'open the floodgates to make
better versions.' PMN310 could be the first of these better
versions. Pre-clinical data show PMN310 can neutralize toxic
oligomers without binding to plaque. Plaque binding is associated
with the dose-limiting brain swelling observed in 35% of the
patients given aducanumab in its phase 3 program. In many chronic
conditions, first generation therapies are often clinically
eclipsed by better versions. PMN310 is on track to provide this
better version, achieving greater therapeutic potency for patients
without the dose-limiting side effect of brain swelling."
("Biogen's good news on aducanumab could 'open the floodgates' for
Alzheimer's drugs," by Dennis J.
Selkoe, October 23, 2019)
To access Dr. Kaplan's narrated deck, click here:
http://bit.ly/ProMIS110719
To learn more about the role of amyloid beta in Alzheimer's
disease including evidence implicating the toxic oligomer, tune
into Saving Minds, at iTunes or Spotify.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology
company focused on discovering and developing antibody therapeutics
selectively targeting toxic oligomers implicated in the development
and progression of neurodegenerative diseases, in particular
Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and
Parkinson's disease (PD). The Company's proprietary target
discovery platform is based on the use of two complementary
thermodynamic, computational discovery engines – ProMIS and
Collective Coordinates – to predict novel targets known as Disease
Specific Epitopes on the molecular surface of misfolded proteins.
Using this unique precision approach, the Company is developing
novel antibody therapeutics for AD, ALS and PD. ProMIS is
headquartered in Toronto, Ontario,
with offices in Cambridge,
Massachusetts. ProMIS is listed on the Toronto Stock
Exchange under the symbol PMN, and on the OTCQB Venture Market
under the symbol ARFXF.
Visit us at www.promisneurosciences.com, follow us
on Twitter and LinkedIn
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-outlines-best-in-class-approach-to-amyloid-beta-targeting-drug-candidates-for-alzheimers-disease-300953376.html
SOURCE ProMIS Neurosciences Inc.